Aytu Biopharma (AYTU) EPS (Basic) Growth (1y) (2015 - 2026)
Powered by 
Analysis
Aytu Biopharma (AYTU) EPS (Basic) Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -15.94% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -108.11% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 39.99% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 13.91% |
| 10 | Aytu Biopharma | 22.49 Mn | -4.22 Mn | 7.60 Mn | -182.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -182.09% |
| Dec 31, 2025 | -903.31% |
| Sep 30, 2025 | -14.32% |
| Jun 30, 2025 | -4,811.10% |
| Mar 31, 2025 | 224.79% |
| Dec 31, 2024 | 401.81% |
| Sep 30, 2024 | 116.40% |
| Jun 30, 2024 | -115.88% |
| Mar 31, 2024 | 73.00% |
| Dec 31, 2023 | 97.98% |
| Sep 30, 2023 | -432.03% |
| Jun 30, 2023 | -92.89% |
| Mar 31, 2023 | 94.62% |
| Dec 31, 2022 | 75.39% |
| Sep 30, 2022 | 98.72% |
| Jun 30, 2022 | 121.16% |
| Dec 31, 2021 | 39.03% |
| Sep 30, 2021 | -207.22% |
| Jun 30, 2021 | 37.26% |
| Dec 31, 2020 | 78.54% |